PKI - PerkinElmer to acquire viral vector gene delivery company SIRION Biotech

PerkinElmer (PKI) to acquire privately held SIRION Biotech GmbH, a global provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies.The acquisition is expected to close during Q3 2021. SIRION has established a strong licensing portfolio leveraged by over a dozen major pharmaceutical and biotech players researching more than twenty five diseases and conditions. The addition of SIRION’s offerings will complement PKI's Horizon Discovery portfolio which includes gene editing and modulation tools for CRISPR, CRISPRi and RNAi, custom cell lines for bio production and base editing technologies.Moreover, the acquisition will further broaden PerkinElmer’s existing cell and gene research solutions.

For further details see:

PerkinElmer to acquire viral vector gene delivery company, SIRION Biotech